Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
April 30, 2015
February 27, 2020
f1b25c36-0d87-42be-b734-ad29acc267ea
Related Documents
Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry
Guidance DocumentMay 14, 2019Center for Drug Evaluation and Research
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
Guidance DocumentApril 28, 2015Center for Drug Evaluation and Research
Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Annex
Guidance DocumentMay 11, 2021Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox